Tuesday, June 17, 2025 6/17/2025

DNA Prime / Subunit Boost Multi-Antigen Universal Influenza Vaccine

Award Number: R43AI122371
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 06/15/2016
PERIOD OF PERFORMANCE END DATE: 05/31/2018

Group Awards By:

View Award Description

DNA Prime / Subunit Boost Multi-Antigen Universal Influenza Vaccine - ABSTRACT A universal influenza vaccine is believed to be possible if conserved regions of influenza are effectively targeted and appropriate immune responses are generated against those targets. The enhanced safety, stability, and accelerated product development generally provided by DNA vaccination make it an appealing approach to develop such a universal influenza vaccine. Unfortunately, immune responses to universal influenza antigens are typically weak and in the past, DNA vaccination of humans has been disappointing. To overcome these and other obstacles to developing an effective, practical, and truly universal influenza vaccine, we intend to deliver our vaccine using a DNA prime / protein boost regimen and employ novel immunogens derived from the following three conserved influenza A antigens: 1) the stem region of hemagglutinin (HA); 2) the matrix 2 protein ectodomain (M2e); and, 3) the nucleoprotein (NP). We believe that together, these antigens will evoke the immunological breadth necessary to protect against a broad range of both seasonal and potential pandemic influenza strains. We will also use a potent DNA adjuvant combination to maximize immunogenicity and to tune the responses toward a Th1 phenotype. Finally, we will utilize a recombinant protein boost to amplify the humoral immune responses and increase their durability. In this Phase I SBIR, we will construct and express our influenza A immunogens and verify their immunogenicity and protective efficacy in mice to determine if the vaccine provides a wide breadth of protection from divergent seasonal and pandemic influenza A strains. If we are successful in this Phase I proof-of-concept study, we will move on to test our vaccine in a macaque challenge model under a Phase II application and begin development on influenza B, and possibly type C, immunogens.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2022 ( Subtotal = -$1,953 )
2022	2016	PROFECTUS BIOSCIENCES, INC.	401 N MIDDLETOWN RD # 205	PEARL RIVER	NY	10965	ROCKLAND	USA	Allergy and Infectious Diseases Research	000	1	10/1/2021	NEW	-$1,953
														Subtotal = -$1,953

Issue Date FY: 2019 ( Subtotal = $0 )
2019	2016	PROFECTUS BIOSCIENCES, INC.	6411 BECKLEY ST STE 201	BALTIMORE	MD	21224	BALTIMORE CITY	USA	Allergy and Infectious Diseases Research	000	1	2/8/2019	NEW	$0
														Subtotal = $0

Issue Date FY: 2016 ( Subtotal = $299,921 )
2016	2016	PROFECTUS BIOSCIENCES INC	6411 BECKLEY STREET	BALTIMORE	MD	21227	BALTIMORE	USA	Allergy and Infectious Diseases Research	000	1	6/14/2016	NEW	$299,921
														Subtotal = $299,921

Grand Total All Awards = $297,968

Top

All Categories

About

Search

Reports

Data Submission

Award Information

DNA Prime / Subunit Boost Multi-Antigen Universal Influenza Vaccine

Award Number: R43AI122371

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 06/15/2016

PERIOD OF PERFORMANCE END DATE: 05/31/2018

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer